Change search
ReferencesLink to record
Permanent link

Direct link
Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Medical and Clinical Genetics.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Obstetrics and Gynaecology.
Show others and affiliations
1999 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 83, no 2, 270-277 p.Article in journal (Refereed) Published
Abstract [en]

We have shown previously that a bispecific antibody (BsAb) directed against both germ-cell alkaline phosphatase (GCAP) and the CD3 complex on mouse T cells could effectively eliminate GCAP-positive tumor cells in vivo using an immunocompetent mouse model. However, some GCAP-negative tumor cells were still able to grow, suggesting that BsAb therapy, when used in a clinical setting, could benefit from targeting several tumor markers to prevent outgrowth of tumor cells lacking a targeted marker. To test this hypothesis, we developed an in vitro model based on primary human ovarian carcinoma (OC) cultures and BsAbs directed against human T cells and several tumor markers [placental alkaline phosphatase (PLAP), GCAP, folate-binding protein (FBP) and CA19.9]. OC cells, isolated from primary tumors, were co-cultured with human peripheral blood mononuclear cells in the presence or absence of various concentrations of BsAbs against PLAP/GCAP, FBP and CA19.9 administered separately or in combination. Results derived from 18 primary OC samples showed that the combination treatment was better than or equally effective as the best single BsAB treatment in 60% of cases. Sometimes targeting FBP, PLAP/GCAP or CA19.9 alone was superior to targeting all simultaneously. Combining each BsAb with a low dose of IL-2 was always beneficial. These results indicate that before using a specific BsAb in the clinic, it is important to determine the optimal BsAb for each patient using this in vitro assay on cells from the removed tumor mass.

Place, publisher, year, edition, pages
1999. Vol. 83, no 2, 270-277 p.
URN: urn:nbn:se:umu:diva-44795DOI: 10.1002/(SICI)1097-0215(19991008)PubMedID: 10471538OAI: diva2:421935
Available from: 2011-06-10 Created: 2011-06-10 Last updated: 2011-06-10Bibliographically approved
In thesis
1. Ovarian tumours, cell isolation, cell survival and sex steroids
Open this publication in new window or tab >>Ovarian tumours, cell isolation, cell survival and sex steroids
2002 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Background: Ovarian cancer is the most deadly malignancy of the female reproductive tract. Ovarian epithelial tumours are considered to be endocrine related, but the factors that govern their genesis and progression remain unclear. Radical surgery and recent advances in chemotherapy have only moderately improved survival rates. Biological and endocrine approaches may help to satisfy the pressing need for alternative therapies.

Aims: The aims of the studies included in this thesis were to isolate and culture ovarian tumour cells with a high epithelial cell fraction (ECF) and to evaluate the fluorometric microculture cytotoxity assay (FMCA) as a tool in the development of alternative therapies. We also aimed to measure the effects of bispecific antibodies (BsAbs) directed against three ovarian tumour markers, separately and in combination, and to study the effects of sex steroids on tumour cell survival, on autonomous steroid secretion and on the expression of estrogen (ER) and progesterone receptors (PR).

Methods: Tumour cells from a total of 75 patient were isolated and cultured in the experiment described by the four papers. The cells were incubated in the presence of BsAbs and peripheral blood mononuclear cells (PBMCs), and at varying concentrations of sex steroids. The FMCA and the neutral red cytotoxity assay were used to measure tumour cell survival. The time-resolved fluoroimmunoassay technique - DELFIA was used to measure steroid concentrations and immunohistochemistry was used to detect tumour markers, ER and PR.

Results and conclusions: It was shown that it is possible to isolate tumour cells from benign as well as malignant tumours, and that the fraction of malignant and atypical cells from carcinoma and borderline tumours can be determined in the cell preparation. Reliable predictive tests such as the FMCA performed on primary cell cultures can make it possible to create individual patinet profiles, thus optimising drug treatment.

Analysis of the BsAbs cultures showed that a combination of the three BsAbs used in our study was the most efficient in tumour cell elimination. In some cases however, the effect of one single BsAb was better than the combination treatment, and this suggests that an optimal therapeutic approach based on BsAbs in a clinical setting requires a panel of BsAbs directed against the commonly expressed ovarian tumour markers.

Tumour cells cultured in 17 β-estradiol and testosterone showed a reduced cell survival and this reduction was inversely proportional to hormone concentrations within the range studied. It was found that 17 β-estradiol was secreted from the primary cell cultures and, interestingly, the amount of 17 β-estradiol secreted increased with increasing levels of 17 β-estradiol in the environment. The majority of the isolated cells analysed for ER and PR expressed both of these receptors to some degree, i.e. the combination ER+/PR+ was the most common. Both ER and PR expression decreased after 72 h culture, revealing an unexpectedly dynamic system. Lowering levels of 17 β-estradiol in cell cultures reduced cell survival, but it appears that this observation depends on factors other than ER. The survival rates of cells cultured in progesterone seemed to be inversely related to their PR expression. It is believed that 17 β-estradiol has an antiapoptotic effect on ovarian surface epithelial (OSE) cells. Reduction of 17 β-estradiol in the environment may inhibit this effect, resulting in reduced cell survival. The ovarian epithelial tumour cell's ability to secrete 17 β-estradiol  suggests that epithelial ovarian tumours play an active role in altering their own hormonal environment, promoting tumour progression.

Place, publisher, year, edition, pages
Umeå: Umeå universitet, 2002. 54 p.
Umeå University medical dissertations, ISSN 0346-6612 ; 799
National Category
Obstetrics, Gynecology and Reproductive Medicine
Research subject
Obstetrics and Gynaecology
urn:nbn:se:umu:diva-44796 (URN)91-7305-271-X (ISBN)
Public defence
2002-09-13, Hörsal E04, byggnad 6E, Norrlands universitetssjukhus, Umeå, 09:00 (English)
Available from: 2011-06-10 Created: 2011-06-10 Last updated: 2011-06-10Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Smans, Karine AIngvarsson, MagdalenaLindgren, PeterStigbrand, TorgnyBäckström, TorbjörnMillán, José Luis
By organisation
Medical and Clinical GeneticsObstetrics and GynaecologyClinical Immunology
In the same journal
International Journal of Cancer

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 23 hits
ReferencesLink to record
Permanent link

Direct link